NCIt definition : A preparation of autologous T-lymphocytes that are genetically engineered to express
a fourth-generation chimeric antigen receptor (4SCAR) targeting the two tumor-associated
antigens (TAAs) disialoganglioside (GD2) and prostate-specific membrane antigen (PSMA),
with potential immunostimulating and antineoplastic activities. Upon administration,
the autologous anti-GD2/anti-PSMA 4SCAR-expressing bispecific T-cells are directed
to and induce selective toxicity in GD2- and PSMA-expressing tumor cells. GD2 is overexpressed
on the surface of neuroblastoma (NB) cells and by other neuroectoderm-derived neoplasms,
while it is minimally expressed on normal cells. PSMA, a type II transmembrane protein,
is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate
tumor cells as well as a variety of other solid tumors, including brain tumor, NB
and some lymphoma tumor tissues.;